SABCS

Measuring Residual Cancer Burden Could Help Improve Predictions of Breast Cancer Outcomes

December 16th 2019, 7:17pm

Article

Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.

Menopausal Hormone Therapy with Estrogen Alone Decreases Breast Cancer Incidence

December 14th 2019, 12:00am

Article

Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.

Partial Breast Irradiation Is Effective in Preventing Recurrence in Patients with Early-Stage Breast Cancer

December 13th 2019, 10:00pm

Article

Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.

Awareness for Men With Breast Cancer is Starting to Take Hold at Major Conferences

December 13th 2019, 9:00pm

Article

This massive event for women with breast cancer just may be “man’s breast friend”.

Arimidex Extends Benefit of Breast Cancer Recurrence Prevention in Postmenopausal Women

December 13th 2019, 3:00am

Article

Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

Adding Immunotherapy to Chemo Before Surgery May Not Improve Response Rates in TNBC

December 13th 2019, 12:41am

Article

Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.

Keytruda Plus Chemotherapy Before and After Surgery Improves Response in Certain Patients with Triple-Negative Breast Cancer

December 12th 2019, 10:31pm

Article

Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

Adding S-1 to Endocrine Therapy Improves Survival in Japanese Patients with Breast Cancer

December 12th 2019, 1:21am

Article

Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.

Addition of Perjeta to Standard Care Improves Survival in HER2-Positive Early Breast Cancer

December 12th 2019, 12:24am

Article

Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.

Pretreated Patients with HER2-Positive Metastatic Breast Cancer See Benefit from Investigational Drug

December 11th 2019, 10:05pm

Article

The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.